Prognosis after Stroke

Stroke

Volumn , Issue , 2011, Pages 219-241

  Rundek, Tatjana ^a   Sacco, Ralph L ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868206578     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5478-8.10015-6     Document Type: Chapter

References (364)

1. Murray C.J.L., Lopez A.D. Mortality by cause for 8 regions of the world: Global burden of disease study. Lancet 1997, 349:1269-1276.
2. Murray C.J.L., Lopez A.D. Global mortality, disability and the contribution of risk factors: Global burden of disease study. Lancet 1997, 349:1436-1442.
3. Wolf A.P., Clagett P., Easton J.D. Preventing ischemic stroke in patients with prior stroke and TIA. A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 1999, 30:1991-1994.
4. Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and risk of stroke and coronary heart disease. Br Med Bull 1994, 50:272-298.
5. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25-146.
6. Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: Results of the prospective designed overviews of randomised trials. Lancet 2000, 356:1955-1964. Blood Pressure Lowering Treatment Trialists' Collaboration.
7. Randomized trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001, 358:1033-1041. PROGRESS Collaborative Group.
8. Effects of an angiotensin-converting-enzyme inhibitor, ramapril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.
9. Amarenco P., Bogousslavsky J., Callahan A. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355(6):549-559.
10. Diener H.C., Bogousslavsky J., Brass L.M. On behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomized, double-blind, placebo-controlled trial. Lancet 2004, 364:331-337.
11. Sacco R.L., Diener H.C., Yusuf S. PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008, 359(12):1238-1251.
12. Romano J.G., Sacco R.L. Progress in secondary stroke prevention. Ann Neurol 2008, 63(4):418-427.
13. National Center for Health Statistics. Vital Statistics of the United States, Data Warehouse. Available at: . Accessed October 29, 2006. http://www.cdc.gov/nchs/data/dvs/MortFinal2003_WorkTable307.pdf.
14. Healthy People 2010: Understanding and improving health November 2000, Department of Health and Human Services, US Government Printing Office, Washington DC. ed 2.
15. Luepker R.V., Arnett D.K., Jacobs D.R. Trends in blood pressure, hypertension control, and stroke mortality: The Minnesota Heart Survey. Am J Med 2006, 119:42-49.
16. Kleindorfer D., Khoury J., Broderick J.P. Temporal trends in public awareness of stroke: Warning signs, risk factors, and treatment. Stroke 2009, 40(7):2502-2506.
17. Gorelick P.B. Stroke prevention therapy beyond antithrombotics: Unifying mechanisms in ischemic stroke pathogenesis and implications for therapy, An invited review. Stroke 2002, 33:862-875.
18. Sacco R.L., Wolf P.A., Gorelick P.B. Risk factors and their management for stroke prevention: Outlook for 1999 and beyond. Neurology 1999, 53(Suppl 4):S15-S24.
19. Wilterdink J.L., Easton J.D. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992, 49:857-863.
20. Sacco R.L. Current Epidemiology of Stroke. Current review of cerebrovascular disease 1993, Current Medicine, Philadelphia. M. Fisher, J. Bogousslavsky (Eds.).
21. Sacco R.L. Prognosis of Stroke. Cerebrovascular disease-Pathophysiology, diagnosis and management. Malden, Mass 1998, 879-891. Blackwell Science. J. Bogousslavsky, M.D. Ginsberg (Eds.).
22. Sacco R.L., Wolf P.A., Kannel W.B., McNamara P.M. Survival and recurrence-The Framingham Study. Stroke 1982, 13:290-295.
23. Howard G., Evans G.W., Murros K.E. Cause specific mortality following cerebral infarction. J Clin Epidemiol 1989, 42:45-51.
24. Rosamond W.D., Folsom A.R., Chambless L.E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerotic Risk in Communities (ARIC) cohort. Stroke 1999, 30:736-774.
25. El-Saed A., Kuller L.H., Newman A.B. Geographic variations in stroke incidence and mortality among older populations in four US communities. Stroke 2006, 37:1975-1979.
26. Petty G.W., Brown R.D., Whisnant J.P., et al. Survival and recurrence after first cerebral infarction: A population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998, 50(1):208-216.
27. Sacco R.L., Shi T., Zamanillo M.C., Kargman D. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan Stroke Study. Neurology 1994, 44:626-634.
28. Fang J., Alderman M.H. Trend of stroke hospitalization, United States, 1988-1997. Stroke 2001, 32(10):2221-2226.
29. D'Alessandro G., Bottacchi E., Di Giovanni M., et al. Temporal trends of stroke in Valle d'Aosta, Italy: incidence and 30-day fatality rates. Neurol Sci 2000, 21:13-18.
30. Mayo N.E., Neville D., Kirkland S., et al. Hospitalization and case-fatality rates for stroke in Canada from 1982 through 1991: The Canadian Collaborative Study Group of Stroke Hospitalizations. Stroke 1996, 27:1215-1220.
31. Truelsen T., Gronbaek M., Schnohr P., Boysen G. Stroke case fatality in Denmark from 1977-1992: The Copenhagen City Heart Study. Neuroepidemiology 2002, 21(1):22-27.
32. Reeves M.J., Smith E., Fonarow G., et al. GWTG-Stroke Steering Committee & Investigators. Off-hour admission and in-hospital stroke case fatality in the Get With The Guidelines stroke program. Stroke 2009, 40(2):569-576.
33. Hartmann A., Rundek T., Mast H., Paik M.C., Boden-Albala B., Mohr J.P., Sacco R.L. Mortality and causes of death after first-ischemic stroke: The Northern Manhattan Stroke Study. Neurology 2001, 57:2000-2005.
34. Loor H.I., Groenier K.H., Limburg M., et al. Risks and causes of death in a community-based stroke population: 1 month and 3 years after stroke. Neuroepidemiology 1999, 18:75-84.
35. Dennis M.S., Burn J.P.S., Sandercock P.A.G., et al. Long-term survival after first-ever stroke: The Oxfordshire Community Stroke Project. Stroke 1993, 24:796-800.
36. Ward G., Jamrozik K., Stewart-Wynne E. Incidence and outcome of cerebrovascular disease in Perth, Western Australia. Stroke 1988, 19:1501-1506.
37. Heuschmann P.U., Kolominsky-Rabas P.L., Misselwitz B., et al. German Stroke Registers Study Group. Predictors of in-hospital mortality and attributable risks of death after ischemic stroke: the German Stroke Registers Study Group. Arch Intern Med 2004, 164(16):1761-1768.
38. van der Worp H.B., Kappelle L.J. Complications of acute ischemic stroke. Cerebrovasc Dis 1998, 8:124-132.
39. Putaala J., Curtze S., Hiltunen S., et al. Causes of death and predictors of 5-year mortality in young adults after first-ever ischemic stroke. The Helsinki Young Stroke Registry. Stroke 2009, 40:2698-2703.
40. Karter A.J., Gazzaniga J.M., Cohen R.D., et al. Ischemic heart disease and stroke mortality in African-American, Hispanic, and non-Hispanic white men and women, 1985 to 1991. West J Med 1998, 169:139-145.
41. Sung J.F., Harris-Hooker S.A., Schmid G., et al. Racial differences in mortality from cardiovascular disease in Atlanta, 1979-1985. J Natl Med Assoc 1992, 84:259-263.
42. Hassaballa H., Gorelick P.B., West C.P., et al. Ischemic stroke outcome: racial differences in the trial of danaparoid in acute stroke (TOAST). Neurology 2001, 57:691-697.
43. Lai S.M., Alter M., Friday G., Sobel E. Prognosis for survival after an initial stroke. Stroke 1995, 26:2011-2015.
44. Baum H.M., Robins M. National Survey of Stroke: Survival and prevalence. Stroke 1981, 12(2 Pt 2 Suppl 1):159-168.
45. Bronnum-Hansen H., Davidsen M., Thorvaldsen P. Danish MONICA Study Group. Long-term survival and causes of death after stroke. Stroke 2001, 32:2131-2136.
46. Gresham G.E., Kelly-Hayes M., Wolf P.A., et al. Survival and functional status 20 or more years after first stroke. The Framingham Study. Stroke 1998, 29:793-797.
47. Wolf P.A., D'Agostino R.B., O'Neal M.A., et al. Secular trends in stroke incidence and mortality. The Framingham Study. Stroke 1992, 23(11):1551-1555.
48. McCarron M.O., Davey Smith G., McCarron P. Secular stroke trends: early life factors and future prospects. QJM 2006, 99(2):117-122.
49. Seshadri S., Beiser A., Kelly-Hayes M., et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke 2006, 37:345-350.
50. Slot K.B., Berge E., Sandercock P., et al. Oxfordshire Community Stroke Project; Lothian Stroke Register; International Stroke Trial (UK). Causes of death by level of dependency at 6 months after ischemic stroke in 3 large cohorts. Stroke 2009, 40(5):1585-1589.
51. WHO MONICA Project (prepared by Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M). Stroke incidence, case fatality, and mortality in the WHO MONICA Project: World Health Organization monitoring trends and determinants in cardiovascular disease, Stroke 26: 361-367 .
52. Lyden P., Brott T., Tilley B., et al. Improved reliability of the NIH stroke scale using video training. Stroke 1994, 25:2220-2226. for the NINDS TPA Stroke Study Group.
53. Adams H.P., Davis P.H., Leira E.C., et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999, 53(1):126-131.
54. Dhamoon M.S., Tai W., Boden-Albala B., et al. Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke 2007, 38(6):1752-1758.
55. Weimar C., Ziegler A., König I.R., Diener H-C Predicting functional outcome and survival after acute ischemic stroke. J Neurol 2002, 249:888-895. on behalf of the German Stroke Study Collaborators.
56. Henon H., Godefry O., Leys D., et al. Early predictors of death after acute cerebral ischemic event. Stroke 1995, 26(3):392-398.
57. Johnston K.C., Connors A.F., Wagner D.P., et al. A predictive risk model for outcomes of ischemic stroke. Stroke 2000, 31(2):448-455.
58. Macciocchi S.N., Diamond P.T., Alves W.M., Mertz T. Ischemic stroke: Relation of age, lesion location, and initial neurologic deficit to functional outcome. Arch Phys Med Rehabil 1998, 79(10):1255-1257.
59. Sankai T., Iso H., Imano H., et al. Survival and disability in stroke by stroke subtype based on computed tomographic findings in three rural Japanese communities. Nippon Koshu Eisei Zasshi 1998, 45(6):552-563.
60. Gargano J.W., Wehner S., Reeves M. Sex differences in acute stroke care in a statewide stroke registry. Stroke 2008, 39(1):24-29.
61. Longstreth W.T., Bernick C., Fitzpatrick A., et al. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology 2001, 56(3):368-375.
62. Ellis C., Zhao Y., Egede L.E. Racial/ethnic differences in stroke mortality in veterans. Ethn Dis 2009, 19(2):161-165.
63. Gentile N.T., Seftchick M.W. Poor outcomes in Hispanic and African American patients after acute ischemic stroke: Influence of diabetes and hyperglycemia. Ethn Dis 2008, 18(3):330-335.
64. Howard G., Howard V.J. REasons for Geographic And Racial Differences in Stroke (REGARDS) Investigators. Ethnic disparities in stroke: the scope of the problem. Ethn Dis 2001, 11(4):761-768.
65. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-1587. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
66. Moroney J.T., Bagiella E., Paik M.C., et al. Risk factors for early recurrence after ischemic stroke: The role of stroke syndrome and subtype. Stroke 1998, 29(10):2118-2124.
67. Weimar C., König I.R., Kraywinkel K., et al. Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models. Stroke 2004, 35(1):158-162. German Stroke Study Collaboration.
68. Censori B., Camerlingo M., Casto L., et al. Prognostic factors in first-ever stroke in the carotid artery territory seen within 6 hours after onset. Stroke 1993, 24:532-535.
69. Albers G.W., Bates V., Clark W.M., et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000, 283:1145-1150.
70. Jansen O., Schellinger P., Fiebach J. Early recanalisation in acute ischaemic stroke saves tissue at risk defined by MRI. Lancet 1999, 353:2036-2037.
71. Adams H.P., Bendixen B.H., Leira E. Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999, 53(1):122-125.
72. Rasmussen D., Kohler O., Worm-Petersen S., et al. Computed tomography in prognostic stroke evaluation. Stroke 1992, 23:506-510.
73. Scmidt E.V., Smirnov V.E., Ryabova V.S. Results of the seven-year prospective study of stroke patients. Stroke 1988, 19:942-949.
74. Bonita R., Ford M.A., Stewart A.W. Predicting survival after stroke: a three-year follow-up. Stroke 1988, 19:669-673.
75. Howard G., Walker M.D., Becker C., et al. Community hospital-based stroke programs: North Carolina, Oregon, and New York. III. Factors influencing survival after stroke: proportional hazards analysis of 4219 patients. Stroke 1986, 17:294-299.
76. Smithard D.G., O'Neill P.A., Parks C., Morris J. Complications and outcome after acute stroke: Does dysphagia matter?. Stroke 1996, 27(7):1200-1204.
77. Bamford J., Sandercock P., Dennis M., et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991, 337:1521-1526.
78. Wang Y., Lim L.L., Levi C. Influence of admission body temperature on stroke mortality. Stroke 2000, 31(2):404-409.
79. Maher J., Hachinski V. Hypothermia as a potential treatment for cerebral ischemia. Cerebrovasc Brain Metab Rev 1993, 5:277-300.
80. Kammersgaard L.P., Jorgensen H.S., Rungby J.A., et al. Admission body temperature predicts long-term mortality after acute stroke: The Copenhagen Stroke Study. Stroke 2002, 33(7):1759-1762.
81. Przelomski M.M., Roth R.M., Gleckman R.A., Marcus E.M. Fever in the wake of a stroke. Neurology 1986, 36:427-429.
82. Castillo J., Martinez F., Leira R., et al. Mortality and morbidity of acute cerebral infarction related to temperature and basal analytic parameters. Cerebrovasc Dis 1994, 4:66-71.
83. Azzimondi G., Bassein L., Nonino F., et al. Fever in acute stroke worsens prognosis: A prospective study. Stroke 1995, 26:2040-2043.
84. Hindfelt B. The prognostic significance of subfebrility and fever in ischaemic cerebral infarction. Acta Neurol Scand 1976, 53:72-79.
85. Castillo J., Davalos A., Marrugat J., Noya M. Timing for fever-related brain damage in acute ischemic stroke. Stroke 1998, 29:2455-2460.
86. Reith J., Jorgensen H.S., Pedersen P.M., et al. Body temperature in acute stroke: Relation to stroke severity, infarct size, mortality, and outcome. Lancet 1996, 347:422-425.
87. Hajat C., Hajat S., Sharma P. Effects of poststroke pyrexia on stroke outcome: A meta-analysis of studies in patients. Stroke 2000, 31:410-414.
88. Schwab S., Georgiadis D., Berrouschpt J., et al. Feasibility and safety of moderate hypothermia after massive hemispheric infarction. Stroke 2001, 32(9):2033-2035.
89. Greer D.M., Funk S.E., Reaven N.L., et al. Impact of fever on outcome in patients with stroke and neurologic injury: A comprehensive meta-analysis. Stroke 2008, 39(11):3029-3035.
90. Dippel D.W., van Breda E.J., van Gemert H.M., et al. Effect of paracetamol (acetaminophen) on body temperature in acute ischemic stroke: a double-blind, randomized phase II clinical trial. Stroke 2001, 32(7):1607-1612.
91. Georgiadis D., Schwarz S., Aschoff A., Schwab S. Hemicraniectomy and moderate hypothermia in patients with severe ischemic stroke. Stroke 2002, 33(6):1584-1588.
92. Georgiadis D., Schwarz S., Kollmar R., Schwab S. Endovascular cooling for moderate hypothermia in patients with acute stroke: First results of a novel approach. Stroke 2001, 32(11):2550-2553.
93. Sacco S.E., Whisnant J.P., Broderick J.P., et al. Epidemiological characteristics of lacunar infarcts in a population. Stroke 1991, 22:1236-1241.
94. Ward G., Jamrozik K., Stewart-Wynne E. Incidence and outcome of cerebrovascular disease in Perth, Western Australia. Stroke 1988, 19:1501-1506.
95. Kolominsky-Rabas P.L., Weber M., Gefeller O., et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria. Incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study, Stroke 2001, 32:2735-2740.
96. Petty G.W., Brown R.D., Whisnant J.P., et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000, 31:1062-1068.
97. Staaf G., Lindgren A., Norrving B. Pure motor stroke from presumed lacunar infarct: Long-term prognosis for survival and risk of recurrent stroke. Stroke 2001, 32(11):2592-2596.
98. de Jong G., van Raak L., Kessels F., Lodder J. Stroke subtype and mortality. a follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol 2003, 56(3):262-268.
99. Adams H.P., Bendixen B.H., Kappelle L.J., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24(1):35-41.
100. Glass T.A., Hennessey P.M., Pazdera L., et al. Outcome at 30 days in the New England Medical Center Posterior Circulation Registry. Arch Neurol 2002, 59(3):369-376.
101. Leonardi-Bee J., Bath P.M., Phillips S.J., Sandercock P.A. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002, 33(5):1315-1320.
102. Rodgers A., MacMahon S., Gamble G., et al. Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ 1996, 313(7050):147.
103. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 1995, 108(9):710-717. PATS Collaborating Group.
104. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):145-153.
105. Britton M., Carlsson A., de Faire U. Blood pressure course in patients with acute stroke and matched controls. Stroke 1986, 17(5):861-864.
106. Robinson T., Waddinton A., Ward-Close S., et al. The predictive role of 24-hour compared to casual blood pressure levels on outcome following acute stroke. Cerebrovasc Dis 1997, 7:264-272.
107. Bath F.J., Bath P.M.W. What is the correct management of blood pressure in acute stroke? The Blood Pressure in Acute Stroke Collaboration. Cerebrovasc Dis 1997, 7:205-213.
108. Tanne D., Kasner S.E., Demchuk A.M. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt-PA Stroke Survey. Circulation 2002, 105(14):1679-1685.
109. Hankey G.J. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis 2003, 16(Suppl 1):14-19.
110. Eriksson S.E., Olsson J.E. Survival and recurrent strokes in patients with different subtypes of stroke: A fourteen-year follow-up study. Cerebrovasc Dis 2001, 12(3):171-180.
111. Howard G., Anderson R., Johnson N.J. Evaluation of social status as a contributing factor to the stroke belt region of the United States. Stroke 1997, 28(5):936-940.
112. Appelros P., Nydevik I., Seiger A., Terent A. Predictors of severe stroke: Influence of preexisting dementia and cardiac disorders. Stroke 2002, 33(10):2357-2362.
113. Jorgensen H.S., Nakayama H., Reith J., et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996, 27(10):1765-1769.
114. Lin H.J., Wolf P.A., Kelly-Hayes M., et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996, 27(10):1760-1764.
115. Sandercock P., Bamford J., Dennis M., et al. Atrial fibrillation and stroke: Prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire Community Stroke Project). BMJ 1992, 305(6867):1460-1465.
116. Henriksson K.M., Farahmand B., Johansson S., et al. Survival after stroke-The impact of CHADS(2) score and atrial fibrillation. Int J Cardiol 2010, 141:18-23.
117. Gottdiener J.S., Gay J.A., VanVoorhees L., et al. Frequency and embolic potential of left ventricular thrombus in dilated cardiomyopathy: Assessment by 2-dimensional echocardiography. Am J Cardiol 1983, 52(10):1281-1285.
118. Al-Khadra A.S., Salem D.N., Rand W.M., et al. Warfarin anticoagulation and survival: A cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998, 31(4):749-753.
119. Kannel W.B., Wolf P.A., Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham Study. JAMA 1983, 250(21):2942-2946.
120. Pullicino P.M., Halperin J.L., Thompson J.L. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000, 54(2):288-294.
121. Kupari M., Lindroos M., Iivanainen A.M., et al. Congestive heart failure in old age: Prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med 1997, 241(5):387-394.
122. Candelise L., Landi G., Orazio E.N., Boccardi E. Prognostic significance of hyperglycemia in acute stroke. Arch Neurol 1985, 42(7):661-663.
123. Kiers L., Davis S.M., Larkins R., et al. Stroke topography and outcome in relation to hyperglycaemia and diabetes. J Neurol Neurosurg Psychiatry 1992, 55(4):263-270.
124. Melamed E. Reactive hyperglycaemia in patients with acute stroke. J Neurol Sci 1976, 29(2-4):267-275.
125. Oppenheimer S.M., Hoffbrand B.I., Oswald G.A., Yudkin J.S. Diabetes mellitus and early mortality from stroke. Br Med J (Clin Res Ed) 1985, 291(6501):1014-1015.
126. Pulsinelli W.A., Levy D.E., Sigsbee B., et al. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med 1983, 74(4):540-544.
127. Williams L.S., Rotich J., Qi R., et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 2002, 59(1):67-71.
128. Bruno A., Levine S.R., Frankel M.R., et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002, 59(5):669-674.
129. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321(7258):405-412.
130. Megherbi S.E., Milan C., Minier D., et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke 2003, 34(3):688-694.
131. Chamorro A., Vila N., Ascaso C., et al. Early prediction of stroke severity. Role of the erythrocyte sedimentation rate. Stroke 1995, 26(4):573-576.
132. Di Napoli M., Papa F., Bocola V. C-reactive protein in ischemic stroke: An independent prognostic factor. Stroke 2001, 32(4):917-924.
133. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107(3):499-511.
134. Rost N.S., Wolf P.A., Kase C.S., et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham Study. Stroke 2001, 32(11):2575-2579.
135. Winbeck K., Poppert H., Etgen T., et al. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002, 33(10):2459-2464.
136. Beamer N.B., Coull B.M., Clark W.M., et al. Persistent inflammatory response in stroke survivors. Neurology 1998, 50(6):1722-1728.
137. Di Tullio M.R., Sacco R.L., Homma S. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 1996, 335(19):1464-1465.
138. Lagrand W.K., Visser C.A., Hermens W.T., et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?. Circulation 1999, 100(1):96-102.
139. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336(14):973-979.
140. Shantikumar S., Grant P.J., Catto A.J., et al. Elevated C-reactive protein and long-term mortality after ischaemic stroke: Relationship with markers of endothelial cell and platelet activation. Stroke 2009, 40(3):977-979.
141. Elkind M.S., Tai W., Coates K., et al. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006, 166(19):2073-2080.
142. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000, 343(16):1148-1155.
143. Elkind M.S., Tai W., Coates K. Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis 2009, 27(1):42-50.
144. Gussekloo J., Schaap M.C., Frolich M., et al. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol 2000, 20(4):1047-1051.
145. Kannel W.B., Anderson K., Wilson P.W. White blood cell count and cardiovascular disease. Insights from the Framingham Study. JAMA 1992, 267(9):1253-1256.
146. Qizilbash N. Fibrinogen and cerebrovascular disease. Eur Heart J 1995, 16(Suppl A):42-45.
147. Tuttolomondo A., Pedone C., Pinto A., et al. Predictors of outcome in acute ischemic cerebrovascular syndromes: The GIFA study. Int J Cardiol 2008, 125(3):391-396.
148. Elkind M.S., Cheng J., Rundek T., et al. Leukocyte count predicts outcome after ischemic stroke: The Northern Manhattan Stroke Study. J Stroke Cerebrovasc Dis 2004, 13(5):220-227.
149. Wong K.Y., MacWalter R.S., Fraser H.W., et al. Urate predicts subsequent cardiac death in stroke survivors. Eur Heart J 2002, 23(10):788-793.
150. Weir C.J., Muir S.W., Walters M.R., Lees K.R. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003, 34(8):1951-1956.
151. Daskalopoulou S.S., Athyros V.G., Elisaf M., Mikhailidis D. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004, 66(4):1714-1715.
152. MacWalter R.S., Wong S.Y., Wong K.Y., et al. Does renal dysfunction predict mortality after acute stroke? A 7-year follow-up study. Stroke 2002, 33(6):1630-1635.
153. Wannamethee S.G., Shaper A.G., Perry I.J. Serum creatinine concentration and risk of cardiovascular disease: A possible marker for increased risk of stroke. Stroke 1997, 28(3):557-563.
154. Yahalom G., Schwartz R., Schwammenthal Y., et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke 2009, 40(4):1296-1303.
155. Nadeau S.E., Jordan J.E., Mishra S.K., Haerer A.F. Stroke rates in patients with lacunar and large vessel cerebral infarctions. J Neurol Sci 1993, 114(2):128-137.
156. Burn J., Dennis M., Bamford J., et al. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994, 25(2):333-337.
157. Hankey G.J., Jamrozik K., Broadhurst R.J., et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998, 29(12):2491-2500.
158. Matsumoto N., Whisnant J.P., Kurland L.T., Okazaki H. Natural history of stroke in Rochester, Minnesota, 1955 through 1969: An extension of a previous study, 1945 through 1954. Stroke 1973, 4(1):20-29.
159. Mohr J.P., Thompson J.L., Lazar R.M., et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001, 345(20):1444-1451.
160. Meissner I., Whisnant J.P., Garraway W.M. Hypertension management and stroke recurrence in a community (Rochester, Minnesota, 1950-1979). Stroke 1988, 19(4):459-463.
161. Moroney J.T., Bagiella E., Paik M.C., et al. Risk factors for early recurrence after ischemic stroke: The role of stroke syndrome and subtype. Stroke 1998, 29(10):2118-2124.
162. Rundek T., Elkind M.S., Chen X., et al. Increased early stroke recurrence among patients with extracranial and intracranial atherosclerosis: The Northern Manhattan Stroke Study. Neurology 1998, (Suppl 4):A75. S09.001.
163. Sacco R.L., Foulkes M.A., Mohr J.P., et al. Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke 1989, 20(8):983-989.
164. Hier D.B., Foulkes M.A., Swiontoniowski M., et al. Stroke recurrence within 2 years after ischemic infarction. Stroke 1991, 22(2):155-161.
165. Hardie K., Hankey G.J., Jamrozik K., et al. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 2004, 35(3):731-735.
166. Peltonen M., Stegmayr B., Asplund K. Time trends in long-term survival after stroke: the Northern Sweden Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) study, 1985-1994. Stroke 1998, 29(7):1358-1365.
167. Hankey G.J., Jamrozik K., Broadhurst R.J., et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 2000, 31(9):2080-2086.
168. Broderick J., Brott T., Kothari R., et al. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998, 29(2):415-421.
169. Lefkovits J., Davis S.M., Rossiter S.C., et al. Acute stroke outcome: Effects of stroke type and risk factors. Aust N Z J Med 1992, 22(1):30-35.
170. Wade D.T., Wood V.A., Hewer R.L. Recovery after stroke-the first 3 months. J Neurol Neurosurg Psychiatry 1985, 48(1):7-13.
171. Jongbloed L. Prediction of function after stroke: a critical review. Stroke 1986, 17(4):765-776.
172. Jorgensen H.S., Nakayama H., Reith J. Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology 1997, 48(4):891-895.
173. Saver J.L., Johnston K.C., Homer D. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators. Stroke 1999, 30(2):293-298.
174. DeGraba T.J., Hallenbeck J.M., Pettigrew K.D., et al. Progression in acute stroke: Value of the initial NIH stroke scale score on patient stratification in future trials. Stroke 1999, 30(6):1208-1212.
175. Hornig C.R., Lammers C., Buttner T., et al. Long-term prognosis of infratentorial transient ischemic attacks and minor strokes. Stroke 1992, 23(2):199-204.
176. Henon H., Godefroy O., Leys D. Early predictors of death and disability after acute cerebral ischemic event. Stroke 1995, 26(3):392-398.
177. Rundek T., Chen X,, Steiner M.M. Predictors of 1-year stroke recurrence: The Northern Manhattan Stroke Study. Cerebrovasc Dis 1997, (Suppl 7):1-88.
178. Fiorelli M., Alperovitch A., Argentino C., et al. Prediction of long-term outcome in the early hours following acute ischemic stroke. Italian Acute Stroke Study Group. Arch Neurol 1995, 52(3):250-255.
179. Alter M., Sobel E., McCoy R.L., et al. Stroke in the Lehigh Valley: Risk factors for recurrent stroke. Neurology 1987, 37(3):503-507.
180. Toni D., Fiorelli M., Bastianello S., et al. Acute ischemic strokes improving during the first 48 hours of onset: predictability, outcome, and possible mechanisms. A comparison with early deteriorating strokes. Stroke 1997, 28(1):10-14.
181. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke: EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993, 342(8882):1255-1262.
182. Amarenco P., Cohen A., Tzourio C., et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994, 331(22):1474-1479.
183. Comess K.A., DeRook F.A., Beach K.W., et al. Transesophageal echocardiography and carotid ultrasound in patients with cerebral ischemia: Prevalence of findings and recurrent stroke risk. J Am Coll Cardiol 1994, 23(7):1598-1603.
184. Di Tullio M., Sacco R.L., Gopal A., et al. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992, 117(6):461-465.
185. Lechat P., Mas J.L., Lascault G., et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988, 318(18):1148-1152.
186. Orencia A.J., Petty G.W., Khandheria B.K., et al. Mitral valve prolapse and the risk of stroke after initial cerebral ischemia. Neurology 1995, 45(6):1083-1086.
187. Webster M.W., Chancellor A.M., Smith H.J., et al. Patent foramen ovale in young stroke patients. Lancet 1988, 2(8601):11-12.
188. Di Tullio M.R., Sacco R.L., Gersony D., et al. Aortic atheromas and acute ischemic stroke: A transesophageal echocardiographic study in an
189. Dhamoon M.S., Sciacca R.R., Rundek T., et al. Recurrent stroke and cardiac risks after first ischemic stroke: The Northern Manhattan Study. Neurology 2006, 66(5):641-646.
190. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis: North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991, 325(7):445-453.
191. Chimowitz M.I., Lynn M.J., Howlett-Smith H., et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005, 352(13):1305-1316.
192. Grau A.J., Weimar C., Buggle F., et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001, 32(11):2559-2566.
193. Petty G.W., Brown R.D., Whisnant J.P., et al. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999, 30(12):2513-2516.
194. Hart R.G., Coull B.M., Hart D. Early recurrent embolism associated with nonvalvular atrial fibrillation: A retrospective study. Stroke 1983, 14(5):688-693.
195. Sage J.I., Van Uitert R.L. Risk of recurrent stroke in patients with atrial fibrillation and non-valvular heart disease. Stroke 1983, 14(4):537-540.
196. Sherman D.G., Hart R.G., Easton J.D. The secondary prevention of stroke in patients with atrial fibrillation. Arch Neurol 1986, 43(1):68-70.
197. Ahmed N., Nasman P., Wahlgren N.G. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 2000, 31(6):1250-1255.
198. Squire I.B., Lees K.R., Pryse-Phillips W., et al. The effects of lifarizine in acute cerebral infarction: A pilot study. Cerebrovasc Dis 1996, 6:156-160.
199. Effect of antihypertensive treatment on stroke recurrence. JAMA 1974, 229(4):409-418. Hypertension-Stroke Cooperative Study Group.
200. Elkind M.S. Outcomes after stroke: risk of recurrent ischemic stroke and other events. Am J Med 2009, 122(4 Suppl 2):S7-S13.
201. Yong M., Kaste M. Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial. Stroke 2008, 39(2):366-372.
202. Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157(21):2413-2446. The sixth report of the Joint National Committee on Prevention.
203. Irie K., Yamaguchi T., Minematsu K., Omae T. The J-curve phenomenon in stroke recurrence. Stroke 1993, 24(12):1844-1849.
204. Voko Z., Bots M.L., Hofman A., et al. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 1999, 34(6):1181-1185.
205. Friday G., Alter M., Lai S.M. Control of hypertension and risk of stroke recurrence. Stroke 2002, 33(11):2652-2657.
206. Gueyffier F., Boissel J.P., Boutitie F., et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997, 28(12):2557-2562.
207. Pergola P.E., White C.L., Graves J.W., et al. Reliability and validity of blood pressure measurement in the Secondary Prevention of Small Subcortical Strokes study. Blood Press Monit 2007, 12(1):1-8.
208. Sobel E., Alter M., Davanipour Z., et al. Stroke in the Lehigh Valley: Combined risk factors for recurrent ischemic stroke. Neurology 1989, 39(5):669-672.
209. Hillen T., Coshall C., Tilling K., et al. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke 2003, 34(6):1457-1463.
210. Bak S., Sindrup S.H., Alslev T., et al. Cessation of smoking after first-ever stroke: A follow-up study. Stroke 2002, 33(9):2263-2269.
211. Wilson K., Gibson N., Willan A., Cook D. Effect of smoking cessation on mortality after myocardial infarction: Meta-analysis of cohort studies. Arch Intern Med 2000, 160(7):939-944.
212. Redfern J., McKevitt C., Dundas R., et al. Behavioral risk factor prevalence and lifestyle change after stroke: A prospective study. Stroke 2000, 31(8):1877-1881.
213. Boysen G., Truelsen T. Prevention of recurrent stroke. Neurol Sci 2000, 21(2):67-72.
214. Gorelick P.B. Alcohol and stroke. Stroke 1987, 18(1):268-271.
215. Camargo C.A. Moderate alcohol consumption and stroke. The epidemiologic evidence. Stroke 1989, 20(12):1611-1626.
216. Gill J.S., Zezulka A.V., Shipley M.J., et al. Stroke and alcohol consumption. N Engl J Med 1986, 315(17):1041-1046.
217. Gorelick P.B., Rodin M.B., Langenberg P., et al. Weekly alcohol consumption, cigarette smoking, and the risk of ischemic stroke: Results of a case-control study at three urban medical centers in Chicago, Illinois. Neurology 1989, 39(3):339-343.
218. Klatsky A.L., Armstrong M.A., Friedman G.D. Alcohol use and subsequent cerebrovascular disease hospitalizations. Stroke 1989, 20(6):741-746.
219. Homma S., Sacco R.L., Di Tullio M.R., et al. Effect of medical treatment in stroke patients with patent foramen ovale: Patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002, 105(22):2625-2631.
220. Sacco R.L., Adams R., Albers G., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke 2006, 37(2):577-617.
221. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 1996, 334(19):1216-1221. The French Study of Aortic Plaques in Stroke Group.
222. Di Tullio M.R., Russo C., Jin Z. Aortic arch plaques and risk of recurrent stroke and death. Circulation 2009, 119(17):2376-2382.
223. Di Napoli M., Papa F. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002, 33(7):1763-1771.
224. Feinberg W.M., Erickson L.P., Bruck D., Kittelson J. Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. Stroke 1996, 27(8):1296-1300.
225. Tohgi H., Konno S., Takahashi S., et al. Activated coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels. Thromb Res 2000, 100(5):373-379.
226. Beamer N., Coull B.M., Sexton G., et al. Fibrinogen and the albumin-globulin ratio in recurrent stroke. Stroke 1993, 24(8):1133-1139.
227. Hankey G.J., Eikelboom J.W. Homocysteine levels in patients with stroke: clinical relevance and therapeutic implications. CNS Drugs 2001, 15(6):437-443.
228. Kittner S.J., Gorelick B. Antiphospholipid antibodies and stroke: an epidemiological perspective. Stroke 1992, 23(Suppl 2):I19-I22.
229. Mayer S.A., Sacco R.L., Hurlet-Jensen A. Free protein S deficiency in acute ischemic stroke. A case-control study. Stroke 1993, 24(2):224-227.
230. Sacco R.L., Owen J., Mohr J.P., et al. Free protein S deficiency: A possible association with cerebrovascular occlusion. Stroke 1989, 20(12):1657-1661.
231. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke: The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology 1993, 43(10):2069-2073.
232. Whiteley W., Chong W.L., Sengupta A., Sandercock P. Blood markers for the prognosis of ischemic stroke: A systematic review. Stroke 2009, 40(5):E380-E389.
233. Caplan L.R. Worsening in ischemic stroke patients: Is it time for a new strategy?. Stroke 2002, 33(6):1443-1445.
234. Ali L.K., Saver J.L. The ischemic stroke patient who worsens: New assessment and management approaches. Rev Neurol Dis 2007, 4(2):85-91.
235. Bromfield E.B., Reding M.J. Relative risk of deep venous thrombosis or pulmonary embolism post-stroke based on ambulatory status. Neurorehabil Neural Repair 1988, 2:51-57.
236. Sherman D.G., Albers G.W., Bladin C. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 2007, 369(9570):1347-1355.
237. Fisher C.M. The use of anticoagulants in cerebral thrombosis. Neurology 1958, 8(5):311-332.
238. Toni D., Fiorelli M., Gentile M., et al. Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis, and prognosis. Arch Neurol 1995, 52(7):670-675.
239. Mohr J.P., Caplan L.R., Melski J.W., et al. The Harvard Cooperative Stroke Registry: a prospective registry. Neurology 1978, 28(8):754-762.
240. Marti-Vilalta J.L., Arboix A. The Barcelona Stroke Registry. Eur Neurol 1999, 41(3):135-142.
241. Yamamoto H., Bogousslavsky J., van Melle G. Different predictors of neurological worsening in different causes of stroke. Arch Neurol 1998, 55(4):481-486.
242. Tei H., Uchiyama S., Ohara K., et al. Deteriorating ischemic stroke in 4 clinical categories classified by the Oxfordshire Community Stroke Project. Stroke 2000, 31(9):2049-2054.
243. Davalos A., Cendra E., Teruel J., et al. Deteriorating ischemic stroke: risk factors and prognosis. Neurology 1990, 40(12):1865-1869.
244. Jorgensen H.S., Nakayama H., Raaschou H.O., Olsen T.S. Effect of blood pressure and diabetes on stroke in progression. Lancet 1994, 344(8916):156-159.
245. Parsons M.W., Barber P.A., Chalk J., et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002, 51(1):28-37.
246. Thijs V.N., Adami A., Neumann-Haefelin T., et al. Clinical and radiological correlates of reduced cerebral blood flow measured using magnetic resonance imaging. Arch Neurol 2002, 59(2):233-238.
247. Christensen H., Boysen G., Johannesen H.H., et al. Deteriorating ischaemic stroke: Cytokines, soluble cytokine receptors, ferritin, systemic blood pressure, body temperature, blood glucose, diabetes, stroke severity, and CT infarction-volume as predictors of deteriorating ischaemic stroke. J Neurol Sci 2002, 201(1-2):1-7.
248. Mohr J.P. Lacunes, Stroke 1982, 13:3-11.
249. Norrving B., Cronqvist S. Clinical and radiologic features of lacunar versus nonlacunar minor stroke. Stroke 1989, 20(1):59-64.
250. Steinke W., Ley S.C. Lacunar stroke is the major cause of progressive motor deficits. Stroke 2002, 33(6):1510-1516.
251. Libman R.B., Sacco R.L., Shi T., Mohr J.P. Spontaneous improvement in pure motor stroke: implications for clinical trials. Neurology 1992, 42:1713-1716.
252. Alberts M.J. Secondary prevention of stroke and the expanding role of the neurologist. Cerebrovasc Dis 2002, 1(Suppl 13):12-16.
253. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360(9326):7-22.
254. McDermott M.M., Lefevre F., Arron M., et al. ST segment depression detected by continuous electrocardiography in patients with acute ischemic stroke or transient ischemic attack. Stroke 1994, 25(9):1820-1824.
255. Diener H.C., Cunha L., Forbes C., et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143(1-2):1-13.
256. CAPRIE Steering Committee. Lancet 1996, 348(9038):1329-1339. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
257. Vickrey B.G., Rector T.S., Wickstrom S.L., et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002, 33(4):901-906.
258. Dexter D.D., Whisnant J.P., Connolly D.C., O'Fallon W.M. The association of stroke and coronary heart disease: A population study. Mayo Clin Proc 1987, 62(12):1077-1083.
259. Salgado A.V., Ferro J.M., Gouveia-Oliveira A. Long-term prognosis of first-ever lacunar strokes. A hospital-based study. Stroke 1996, 27(4):661-666.
260. Gorelick P.B., Richardson D., Kelly M., et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial. JAMA 2003, 289(22):2947-2957.
261. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
262. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 1996, 27(9):1453-1458. The RANTTAS Investigators.
263. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15(4):361-387.
264. Baird A.E., Benfield A., Schlaug G., et al. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 1997, 41(5):581-589.
265. Fisher M., Albers G.W. Applications of diffusion-perfusion magnetic resonance imaging in acute ischemic stroke. Neurology 1999, 52(9):1750-1756.
266. Singer M.B., Chong J., Lu D., et al. Diffusion-weighted MRI in acute subcortical infarction. Stroke 1998, 29(1):133-136.
267. Warach S., Gaa J., Siewert B., et al. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol 1995, 37(2):231-241.
268. Baird A.E., Dambrosia J., Janket S., et al. A three-item scale for the early prediction of stroke recovery. Lancet 2001, 357(9274):2095-2099.
269. Thijs V.N., Lansberg M.G., Beaulieu C., et al. Is early ischemic lesion volume on diffusion-weighted imaging an independent predictor of stroke outcome? A multivariable analysis. Stroke 2000, 31(11):2597-2602.
270. Hand P.J., Wardlaw J.M., Rivers C.S., et al. MR diffusion-weighted imaging and outcome prediction after ischemic stroke. Neurology 2006, 66(8):1159-1163.
271. Wardlaw J.M., Keir S.L., Bastin M.E., et al. Is diffusion imaging appearance an independent predictor of outcome after ischemic stroke?. Neurology 2002, 59(9):1381-1387.
272. Johnston K.C., Wagner D.P., Wang X.Q. Validation of an acute ischemic stroke model: does diffusion-weighted imaging lesion volume offer a clinically significant improvement in prediction of outcome?. Stroke 2007, 38(6):1820-1825.
273. Barrett K.M., Ding Y.H., Wagner D.P., et al. Change in diffusion-weighted imaging infarct volume predicts neurologic outcome at 90 days: Results of the Acute Stroke Accurate Prediction (ASAP) trial serial imaging substudy. Stroke 2009, 40(7):2422-2427.
274. Johnston S.C., Gress D.R., Browner W.S., Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000, 284(22):2901-2906.
275. Kernan W.N., Viscoli C.M., Brass L.M., et al. The stroke prognosis instrument II (SPI-II): A clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. Stroke 2000, 31(2):456-462.
276. Diener H.C., Ringleb P.A., Savi P. Clopidogrel for the secondary prevention of stroke. Expert Opin Pharmacother 2005, 6(5):755-764.
277. Diener H.C. Modified-release dipyridamole combined with aspirin for secondary stroke prevention. Aging Health 2005, 1:19-26.
278. Weimar C., Diener H.C., Alberts M.J., et al. The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry. Stroke 2009, 40(2):350-354.
279. Wade D.T., Collin C. The Barthel ADL Index: a standard measure of physical disability?. Int Disabil Stud 1988, 10(2):6467.
280. Wade D.T., Hewer R.L. Functional abilities after stroke: Measurement, natural history and prognosis. J Neurol Neurosurg Psychiatry 1987, 50(2):177-182.
281. Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957, 2(5):200-215.
282. Granger C.V., Hamilton B.B., Gresham G.E., Kramer A.A. The stroke rehabilitation outcome study: Part II. Relative merits of the total Barthel index score and a four-item subscore in predicting patient outcomes. Arch Phys Med Rehabil 1989, 70(2):100-103.
283. Sacco R.L., DeRosa J.T., Haley E.C., et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: A randomized controlled trial. JAMA 2001, 285(13):1719-1728.
284. Dennis M.S., Burn J.P., Sandercock P.A., et al. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1993, 24(6):796-800.
285. Dombovy M.L., Basford J.R., Whisnant J.P., Bergstralh E.J. Disability and use of rehabilitation services following stroke in Rochester, Minnesota, 1975-1979. Stroke 1987, 18(5):830-836.
286. Hackett M.L., Duncan J.R., Anderson C.S., et al. Health-related quality of life among long-term survivors of stroke: Results from the Auckland Stroke Study, 1991-1992. Stroke 2000, 31(2):440-447.
287. Hankey G.J., Jamrozik K., Broadhurst R.J., et al. Long-term disability after first-ever stroke and related prognostic factors in the Perth Community Stroke Study, 1989-1990. Stroke 2002, 33(4):1034-1040.
288. Kojima S., Omura T., Wakamatsu W., et al. Prognosis and disability of stroke patients after 5 years in Akita, Japan. Stroke 1990, 21(1):72-77.
289. Bamford J., Sandercock P., Dennis M. A prospective study of acute cerebrovascular disease in the community: The Oxfordshire Community Stroke Project-1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1990, 53(1):16-22.
290. Bonita R., Beaglehole R. Recovery of motor function after stroke. Stroke 1988, 19(12):1497-1500.
291. Carolei A., Marini C., Di Napoli M., et al. High stroke incidence in the prospective community-based L'Aquila registry (1994-1998). First year's results. Stroke 1997, 28(12):2500-2506.
292. Greveson G.C., Gray C.S., French J.M., James O.F. Long-term outcome for patients and carers following hospital admission for stroke. Age Ageing 1991, 20(5):337-344.
293. Kappelle L.J., Adams H.P., Heffner M.L., et al. Prognosis of young adults with ischemic stroke. A long-term follow-up study assessing recurrent vascular events and functional outcome in the Iowa Registry of Stroke in Young Adults. Stroke 1994, 25(7):1360-1365.
294. Korv J., Roose M., Haldre S., Kaasik A.E. Registry of first-ever stroke in Tartu, Estonia, 1991 through 1993: Outcome of stroke. Acta Neurol Scand 1999, 99(3):175-181.
295. Sturm J.W., Dewey H.M., Donnan G.A., et al. Handicap after stroke: How does it relate to disability, perception of recovery, and stroke subtype? The North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2002, 33(3):762-768.
296. Taub N.A., Wolfe C.D., Richardson E., Burney P.G. Predicting the disability of first-time stroke sufferers at 1 year. 12-month follow-up of a population-based cohort in southeast England. Stroke 1994, 25(2):352-357.
297. Wilkinson P.R., Wolfe C.D., Warburton F.G., et al. A long-term follow-up of stroke patients. Stroke 1997, 28(3):507-512.
298. Wolfe C.D., Taub N.A., Bryan S., et al. Variations in the incidence, management and outcome of stroke in residents under the age of 75 in two health districts of southern England. J Public Health Med 1995, 17(4):411-418.
299. Woo J., Yuen Y.K., Kay R., Nicholls M.G. Survival, disability, and residence 20 months after acute stroke in a Chinese population: Implications for community care. Disabil Rehabil 1992, 14(1):36-40.
300. Lo R.S., Cheng J.O., Wong E.M., et al. Handicap and its determinants of change in stroke survivors: One-year follow-up study. Stroke 2008, 39(1):148-153.
301. Huybrechts K.F., Caro J.J. The Barthel Index and modified Rankin Scale as prognostic tools for long-term outcomes after stroke: A qualitative review of the literature. Curr Med Res Opin 2007, 23(7):1627-1636.
302. rd Annual Meeting of the American Neurological Association, Montreal. Canada 1998, T205:79-80.
303. World Health Organization International classification of impairments, disabilities and handicaps 1980, WHO, Geneva, Switzerland.
304. Walker M.F., Gladman J.R., Lincoln N.B., et al. Occupational therapy for stroke patients not admitted to hospital: A randomised controlled trial. Lancet 1999, 354(9175):278-280.
305. Jenkinson C., Mant J., Carter J., et al. The London handicap scale: A re-evaluation of its validity using standard scoring and simple summation. J Neurol Neurosurg Psychiatry 2000, 68(3):365-367.
306. Anderson C.S., Taylor B.V., Hankey G.J., et al. Validation of a clinical classification for subtypes of acute cerebral infarction. J Neurol Neurosurg Psychiatry 1994, 57(10):1173-1179.
307. Wolfe C.D., Taub N.A., Woodrow E.J., Burney P.G. Assessment of scales of disability and handicap for stroke patients. Stroke 1991, 22(10):1242-1244.
308. Saver J.L. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007, 38(11):3055-3062.
309. Bath P.M., Gray L.J., Collier T., et al. Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke 2007, 38(6):1911-1915.
310. Angeleri F., Angeleri V.A., Foschi N., et al. The influence of depression, social activity, and family stress on functional outcome after stroke. Stroke 1993, 24(10):1478-1483.
311. Labi M.L., Phillips T.F., Greshman G.E. Psychosocial disability in physically restored long-term stroke survivors. Arch Phys Med Rehabil 1980, 61(12):561-565.
312. Lawrence L., Christie D. Quality of life after stroke: A three-year follow-up. Age Ageing 1979, 8(3):167-172.
313. Guyatt G.H., Feeny D.H., Patrick D.L. Measuring health-related quality of life. Ann Intern Med 1993, 118(8):622-629.
314. Sturm J.W., Donnan G.A., Dewey H.M., et al. Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2004, 35(10):2340-2345.
315. EuroQOl-a new facility for the measurement of health-related quality of life. Health Policy 1990, 16(3):199-208. The EuroQOl Group.
316. Bergner M., Bobbitt R.A., Kressel S., et al. The sickness impact profile: conceptual formulation and methodology for the development of a health status measure. Int J Health Serv 1976, 6(3):393-415.
317. Duncan P.W., Lai S.M., Tyler D., et al. Evaluation of proxy responses to the Stroke Impact Scale. Stroke 2002, 33(11):2593-2599.
318. Kaplan R.M., Bush J.W. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol 1982, 1:61-67.
319. McEwen M.J. The Nottingham Health Profile. Quality of Life: Assessment and application. Lancaster 1988, MTp Press, England. S.R. Walker, R.M. Rosser (Eds.).
320. Roberts L., Counsell C. Assessment of clinical outcomes in acute stroke trials. Stroke 1998, 29(5):986-991.
321. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483.
322. Kasner S.E. Clinical interpretation and use of stroke scales. Lancet Neurol 2006, 5(7):603-612.
323. Duncan P.W., Wallace D., Lai S.M., et al. The stroke impact scale version 2.0. Evaluation of reliability, validity, and sensitivity to change. Stroke 1999, 30(10):2131-2140.
324. Sacco R.L., Boden-Albala B., Kargman D.E., Gu Q. Quality of life after ischemic stroke: The Northern Manhattan Stroke Study. Ann Neurol 1995, 38:322.
325. de Haan R.J. Measuring quality of life after stroke using the SF-36. Stroke 2002, 33(5):1176-1177.
326. Williams L.S., Weinberger M., Harris L.E., Biller J. Measuring quality of life in a way that is meaningful to stroke patients. Neurology 1999, 53(8):1839-1843.
327. Salter K.L., Moses M.B., Foley N.C., Teasell R.W. Health-related quality of life after stroke: What are we measuring?. Int J Rehabil Res 2008, 31(2):111-117.
328. Simon G.E., Revicki D.A., Grothaus L., Vonkorff M. SF-36 summary scores: are physical and mental health truly distinct?. Med Care 1998, 36(4):567-572.
329. Taft C., Karlsson J., Sullivan M. Do SF-36 summary component scores accurately summarize subscale scores?. Qual Life Res 2001, 10(5):395-404.
330. Wilson D., Parsons J., Tucker G. The SF-36 summary scales: problems and solutions. Soz Praventivmed 2000, 45(6):239-246.
331. Van der Linden W.J., Hambleton R.K. Handbook of modern item response theory 1997, Springer, New York.
332. Fayers P.M., Machin D. Quality of life: Assessment, analysis and interpretation 2000, John Wiley & Sons, London, England, pp 85-87.
333. Burvill P.W., Johnson G.A., Jamrozik K.D., et al. Prevalence of depression after stroke: The Perth Community Stroke Study. Br J Psychiatry 1995, 166(3):320-327.
334. House A., Dennis M., Mogridge L., et al. Mood disorders in the year after first stroke. Br J Psychiatry 1991, 158:83-92.
335. Whyte E.M., Mulsant B.H. Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry 2002, 52(3):253-264.
336. Hackett M.L., Yapa C., Parag V., Anderson C.S. Frequency of depression after stroke: A systematic review of observational studies. Stroke 2005, 36(6):1330-1340.
337. Lenze E.J., Rogers J.C., Martire L.M., et al. The association of late-life depression and anxiety with physical disability: A review of the literature and prospectus for future research. Am J Geriatr Psychiatry 2001, 9(2):113-135.
338. Austin M.P., Mitchell P., Goodwin G.M. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry 2001, 178:200-206.
339. Butters M.A., Becker J.T., Nebes R.D., et al. Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry 2000, 157(12):1949-1954.
340. Schulz R., Beach S.R., Ives D.G., et al. Association between depression and mortality in older adults: The Cardiovascular Health Study. Arch Intern Med 2000, 160(12):1761-1768.
341. Astrom M., Adolfsson R., Asplund K. Major depression in stroke patients. A 3-year longitudinal study. Stroke 1993, 24(7):976-982.
342. Herrmann N., Black S.E., Lawrence J., et al. The Sunnybrook Stroke Study: A prospective study of depressive symptoms and functional outcome. Stroke 1998, 29(3):618-624.
343. Kauhanen M., Korpelainen J.T., Hiltunen P., et al. Poststroke depression correlates with cognitive impairment and neurological deficits. Stroke 1999, 30(9):1875-1880.
344. Pohjasvaara T., Leppavuori A., Siira I., et al. Frequency and clinical determinants of poststroke depression. Stroke 1998, 29(11):2311-2317.
345. Singh A., Black S.E., Herrmann N., et al. Functional and neuroanatomic correlations in poststroke depression: The Sunnybrook Stroke Study. Stroke 2000, 31(3):637-644.
346. Vataja R., Pohjasvaara T., Leppavuori A., et al. Magnetic resonance imaging correlates of depression after ischemic stroke. Arch Gen Psychiatry 2001, 58(10):925-931.
347. Hackett M.L., Anderson C.S. Predictors of depression after stroke: A systematic review of observational studies. Stroke 2005, 36(10):2296-2301.
348. Gillen R., Tennen H., McKee T.E., et al. Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients. Arch Phys Med Rehabil 2001, 82(12):1645-1649.
349. Paolucci S., Antonucci G., Grasso M.G., et al. Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study. Cerebrovasc Dis 2001, 12(3):264-271.
350. House A., Knapp P., Bamford J., Vail A. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke 2001, 32(3):696-701.
351. Parikh R.M., Robinson R.G., Lipsey J.R., et al. The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. Arch Neurol 1990, 47(7):785-789.
352. Schubert D.S., Taylor C., Lee S., et al. Detection of depression in the stroke patient. Psychosomatics 1992, 33(3):290-294.
353. Beck A.T., Ward C.H., Mendelson M., et al. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
354. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
355. Salter K., Bhogal S.K., Foley N., et al. The assessment of poststroke depression. Top Stroke Rehabil 2007, 14(3):1-24.
356. Robinson R.G., Bolduc P.L., Price T.R. Two-year longitudinal study of poststroke mood disorders: Diagnosis and outcome at one and two years. Stroke 1987, 18(5):837-843.
357. Beblo T., Wallesch C.W., Herrmann M. The crucial role of frontostriatal circuits for depressive disorders in the postacute stage after stroke. Neuropsychiatry Neuropsychol Behav Neurol 1999, 12(4):236-246.
358. Gainotti G., Azzoni A., Marra C. Frequency, phenomenology and anatomical-clinical correlates of major post-stroke depression. Br J Psychiatry 1999, 175:163-167.
359. Katz I. Presidential address: On the inseparability of mental and physical health in aged persons: Lessons from depression and medical comorbidity. Am J Geriatr Psychiatry 1996, 4(1):1-16.
360. Kotila M., Numminen H., Waltimo O., Kaste M. Depression after stroke: Results of the FINNSTROKE Study. Stroke 1998, 29(2):368-372.
361. Downhill J.E., Robinson R.G. Longitudinal assessment of depression and cognitive impairment following stroke. J Nerv Ment Dis 1994, 182(8):425-431.
362. Alexopoulos G.S., Meyers B.S., Young R.C., et al. Clinically defined vascular depression. Am J Psychiatry 1997, 154(4):562-565.
363. Robinson R.G., Jorge R.E., Moser D.J., et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: A randomized controlled trial. JAMA 2008, 299(20):2391-2400.
364. Chen Y., Patel N.C., Guo J.J., Zhan S. Antidepressant prophylaxis for poststroke depression: A meta-analysis. Int Clin Psychopharmacol 2007, 22(3):159-166.